News
Press releases
June 18, 2025
Atalanta Therapeutics Announces Leadership TransitionsApril 8, 2025
Atalanta Therapeutics Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related EpilepsyJanuary 28, 2025
Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical TrialPresentations & Publications
News
In the News
January 11, 2021
Endpoints News“Genentech and Biogen roll the dice on an upstart biotech with a new siRNA approach — going deep into the brain for targets in neurodegeneration”
October 14, 2019
Nature Biotechnology“Two new startups, Triplet Therapeutics and Atalanta Therapeutics, are pushing to bring genetic medicine to patients with Huntington’s disease, adding momentum to an industry drive that was galvanized last year…”